In the liver, SIRT1 activity decreases de novo lipogenesis by suppressing the activity of the transcription factor SREBP-1c, while AMPK up-regulates free fatty acid oxidation via inhibition of acetyl-CoA carboxylase—effects that are useful for management of non-alcoholic fatty liver disease [173,174]. This evidence concerns the gene SIRT1 and metabolic dysfunction-associated steatotic liver disease.